Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The group will offer free access to omic and clinical data from the project and develop software to help clinicians use the models in patient care.
The partners have planned a three-year pilot and selected three NCI projects to benefit from supercomputers and expertise offered by four DOE labs.
Myriad Genetics, Kinaxo Biotechnologies, Bavarian Research Foundation, European Commission, Decode Genetics, Ontario Institute for Cancer Research
The $3.8 million program will back assay development, screening tools, toxicity, and elucidation of 3D structures in search of HIV treatments
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.